Treatment of Uncomplicated Malaria in Benin

April 11, 2008 updated by: Institut de Recherche pour le Developpement

Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study

Malaria is a life-threatening disease especially in small children. A high degree of Plasmodium falciparum resistance to chloroquine has already spread to South-Benin where this study is taking place. In the past few years, the recommendation for a first-line treatment in this area has moved from chloroquine to sulfadoxine-pyrimethamine (SP). There is growing evidence that Plasmodium falciparum resistance to SP has come to South-Benin. The aim of the study is to compare the efficacy of SP to two compact artemisinin-based therapies (ACT): artemether-lumefantrine and the amodiaquine-artesunate coformulation. ACT will be unsupervised.

The primary endpoint is an effectiveness comparison (PCR corrected) at day 28. Secondary outcomes are effectiveness comparisons (PCR corrected) at day 14 and 42 and a study on the relationships between ACT PK data (day 3) and outcome.

Expected total enrollment: 225 patients

Study start: April 2007; expected completion: December 2007

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

240

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Benin
      • Allada, Benin
        • Centre de santé

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 9 years (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 6-119 months old
  • fever or history of fever of less than 24 hours
  • p falciparum parasitemia > 1000 trophozoïtes/µL
  • informed consent signed

Exclusion Criteria:

  • < 5 kg
  • danger or severity signs of malaria
  • known underlying chronic disease
  • Hb < 5g/dL
  • adequate malaria treatment taken within 3 days before visit

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: 1
sulfadoxine-pyrimethamine
Drug: sulfadoxine-pyrimethamine

tablets 1,25/25 mg

1 tablet per 20 kg of body weight Single drug intake

Other Names:
  • Fansidar
ACTIVE_COMPARATOR: 2
artemether-lumefantrine
Drug: artemether-lumefantrine

tablets 20/120 mg

  • 1 tablet twice daily for 3 days below 15 kg of bodyweight
  • 2 tablets twice daily for 3 days below 24 kg of bodyweight
  • 3 tablets twice daily for 3 days below 35 kg of bodyweight
Other Names:
  • coartem
ACTIVE_COMPARATOR: 3
amodiaquine-artesunate coformulation
Drug: amodiaquine-artesunate coformulation

one 25mg/67,5mg tablet, once daily for 3 days below 9 kg

one 50/135mg tablet, once daily for 3 days below 18 kg

Other Names:
  • coarsucam

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
efficacy
Time Frame: day 28
day 28

Secondary Outcome Measures

Outcome Measure
Time Frame
effectiveness comparisons (PCR corrected)
Time Frame: day 14 and day 42
day 14 and day 42
incidence of adverse events
Time Frame: day 42
day 42

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut de Recherche pour le Developpement

Investigators

  • Principal Investigator: Jean-François Faucher, MD PhD, Institut de Recherche pour le Développement UR010
  • Study Director: Philippe Deloron, MD PhD, Institut de Recherche pour le Développement UR010

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2007

Primary Completion (ACTUAL)

November 1, 2007

Study Completion (ACTUAL)

November 1, 2007

Study Registration Dates

First Submitted

April 12, 2007

First Submitted That Met QC Criteria

April 12, 2007

First Posted (ESTIMATE)

April 13, 2007

Study Record Updates

Last Update Posted (ESTIMATE)

April 14, 2008

Last Update Submitted That Met QC Criteria

April 11, 2008

Last Verified

April 1, 2008

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Malariallada

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe